Skip to main content

Table 4 Historical Survival Data of the Patients with BVI, LyVI or LVI Positive Stage IA NSCLC

From: A single-arm, phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study

Author Year T-Classification Vessel invasion status Number of Patients 5-year Survival Rates (%)
Overall Relapse free
Pechet et al. [6] 2004 T1 BVI 22 28
Tsuchiya et al. [9] 2007 T1 LVI (BVI or LyVI) 85 71.8
Tsuchiya et al. [10] 2007 T1 LVI (BVI or LyVI) 144 78.7
Miyoshi et al. [11] 2009 T1 LVI (BVI or LyVI) 62 78
Funai et al. [12] 2011 T1 LyVI 22 70.9
Ito et al. [16] 2012 T1 LVI (BVI or LyVI) 105 58
Shimada et al. [14] 2012 T1 BVI 116 72.1 71.3
   LyVI 122 76.4 76.1
Kudo et al. [17] 2013 T1a BVI 38 87.1 72.5
  T1b BVI 39 65.9 58.9
Hamanaka et al. [19] 2015 T1 LVI (BVI or LVI) 56 79.7
Present series 2018 T1 LVI (BVI or LVI) 52 94.2 88.5
  1. BVI Blood vessel invasion, LVI Lymphovascular invasion, LyVI Lymphatic vessel invasion
\